A drug utilization study of thiocolchicoside-containing medicinal products for systemic use in France and Italy: A cross-sectional electronic medical records database study
- PMID: 36919414
- DOI: 10.1002/pds.5611
A drug utilization study of thiocolchicoside-containing medicinal products for systemic use in France and Italy: A cross-sectional electronic medical records database study
Abstract
Purpose: The risk minimization measures (RMM) for systemic use of thiocolchicoside (TCC) was implemented across Europe during 2014-2016. RMM included restriction of use in age <16 years, maximum dose and duration, chronic conditions, contraindication in pregnancy, lactation or in women of childbearing potential [WOCBP] without appropriate contraception. The current Drug Utilization Study was aimed to describe the prescribing practices of TCC in France and Italy.
Method: The study analyzed data (demographic, prescription, diagnosis, and concomitant treatment) from electronic medical record databases. It compares drug utilization during pre-implementation (baseline: year 2013) and post-implementation (years 1, 2, and 3) of RMM. This study included panels of general practitioners (FGP) and rheumatologists (FRH) in France and Italy (IGP).
Results: TCC was largely prescribed as adjuvant therapy in both pre-implementation (FGP: 93.5%, FRH: 88.8%, IGP: 86.6%) and post-implementation (FGP: 92.3%, FRH: 89.5%, IGP: 89.0%) periods. Prescribing patterns were different in France and Italy, with FGP and FRH mainly prescribing oral formulation (>95% and >80%, respectively), while IGP prescribing intramuscular formulation (>70%). Prescriptions to patients aged ≥16 years were >99% in all panels during both periods. An improvement was observed in compliance with treatment duration for oral formulation in the FGP panel post-implementation versus pre-implementation (66.2% vs. 46.7%; p < 0.001). There was no change in prescription rate post RMM implementation in pregnant (FGP: 0.5%, IGP: 4.7%) and in WOCBP without appropriate contraception (FGP: 89.3%, IGP: 93.4%).
Conclusion: These results highlighted changes in prescribing practices of TCC after RMM implementation, which varied across panels and measures.
Keywords: contraception; drug utilization study; prescription; risk minimization measures; safety; thiocolchicoside.
© 2023 Sanofi Winthrop Industrie. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Janbroers JM. Review of the toxicology, pharmacodynamics and pharmacokinetics of thiocolchicoside, a GABA-agonist muscle relaxant with anti-inflammatory and analgesic actions. Acta Ther. 1987;13(3):221-250.
-
- Carta M, Murru L, Botta P, et al. The muscle relaxant thiocolchicoside is an antagonist of GABAA receptor function in the central nervous system. Neuropharmacology. 2006;51(4):805-815.
-
- Ketenci A, Ozcan E, Karamursel S. Assessment of efficacy and psychomotor performances of thiocolchicoside and tizanidine in patients with acute low back pain. Int J Clin Pract. 2005;59(7):764-770.
-
- Agency EM. Thiocolchicoside containing medicinal products Article-31 referral assessment report. Committee for Medicinal Products for Human Use (CHMP). 2014.
-
- Agency EM. European Medicines Agency recommends restricting use of thiocolchicoside by mouth or injection. 2013.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
